دوره 17، شماره 4 - ( 7-1405 )                   جلد 17 شماره 4 صفحات 0-16 | برگشت به فهرست نسخه ها

Ethics code: IR.SBMU.MSP.REC.1403.594

XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salimi M, Salimi B, Rezvani H, Pourghasemian M, Beyramzadeh E, Mirzaei M H et al . Safety and Outcomes of Etoposide as a Substitute for Radiotherapy in Primary mediastinal B-cell lymphoma Treatment. , Caspian J Intern Med. 2026; 17 (4) :16
URL: http://caspjim.com/article-1-5083-fa.html
Safety and Outcomes of Etoposide as a Substitute for Radiotherapy in Primary mediastinal B-cell lymphoma Treatment. ، . 1405; 17 (4) :16

URL: http://caspjim.com/article-1-5083-fa.html


چکیده:   (5 مشاهده)
Background: Primary mediastinal B-cell lymphoma (PMBCL) is a unique subtype of diffuse large B-cell lymphoma. There are some concerns regarding the long-term toxicity of radiotherapy treatment. We compared clinical outcomes and recorded adverse events between DA-EPOCH-R without planned radiotherapy and R-CHOP followed by mediastinal consolidation.
Methods: Medical records of 91 adults with PMBCL treated at Dr. Masih Daneshvari Hospital between 2019 and 2024 were retrospectively reviewed. Forty-six patients received DA-EPOCH-R without planned radiotherapy, whereas 45 received R-CHOP followed by mediastinal radiotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were three-year overall survival (OS), complete metabolic response (CMR), defined as a Deauville score of 1–3 on PET-CT performed three months after treatment completion, and documented adverse events.
Results: Median PFS was 12 months in the DA-EPOCH-R group and 13 months in the R-CHOP plus radiotherapy group (log-rank p=0.808). Treatment regimen was unrelated to PFS after adjustment for age and sex (adjusted HR, 1.03; 95% CI, 0.66–1.61; p=0.884).Three-year OS was 91.3% versus 93.3% (p=0.716), and CMR rates were 87.0% versus 95.6% (p=0.148), respectively. Fever and neutropenia were less frequently documented in the DA-EPOCH-R group (p=0.019 and p=0.001, respectively).
Conclusion:  PFS, three-year OS, and CMR did not differ significantly between the treatment strategies. Fever and neutropenia were less frequently documented with DA-EPOCH-R.
     
نوع مطالعه: Original Article | موضوع مقاله: Oncology
دریافت: 1404/11/26 | پذیرش: 1405/8/19 | انتشار: 1405/6/18

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2026 CC BY-NC 4.0 | Caspian Journal of Internal Medicine

Designed & Developed by : Yektaweb